U.S. TRIPTORELIN MARKET ANALYSIS

Market Challenges And Opportunities

Moreover, in the year 2020, Arbor Pharmaceuticals, LLC, confirmed that it has ordered supply of Triptodur (triptorelin) for its partner Debiopharm, in order to avoid the shortage during the COVID-19 pandemic.

U.S. Triptorelin Market – Restraints

U.S. triptorelin market growth is expected to be hampered in the near future, owing to side effects that have been recorded by the U.S. Food and Drug Administration (FDA). For instance, the U.S. FDA, in the year 2019, updated the side-effects for triptorelin that have been observed in the patients who are taking these medicines. They worsen the symptoms during tumor flare, hot flushes, decreased libido and impotence, bone and joint pain (may be increased initially), injection site reactions (pain, mild bruising, and erythema), sweating and weight gain.

Market Drivers

Manufacturers are providing reimbursement for the drug triptorelin and other resources, this is expected to attract the patients for choosing triptorelin for their treatment. This will drive the growth of the U.S. triptorelin market over the forecast period.

For instance, in the year 2022, Arbor Pharmaceuticals, LLC, subsidiary of Azurity Pharmaceuticals, Inc. is currently offering reimbursement for the patients undergoing treatment for central precocious puberty (CPP) with Triptodur (triptorelin). The company is providing the drug at a low cost so that all the patients can afford the drug. Under this reimbursement policy, the patient can save almost US$ 10,000 per year. The offer is valid in the U.S. and Puerto Rico as allowed by law. Under the policy, only those patients are eligible for the reimbursement policy, who are insured in whole or in part, by Medicaid, Medicare, or other federal or state healthcare programs. 

U.S. Triptorelin Market – Restraints

U.S. triptorelin market growth is expected to be hampered in the near future, owing to side effects that have been recorded by the U.S. Food and Drug Administration (FDA). For instance, the U.S. FDA, in the year 2019, updated the side-effects for triptorelin that have been observed in the patients who are taking these medicines. They worsen the symptoms during tumor flare, hot flushes, decreased libido and impotence, bone and joint pain (may be increased initially), injection site reactions (pain, mild bruising, and erythema), sweating and weight gain.

U.S. Triptorelin Market – Competitive Landscape